Decheng Capital LLC Scynexis Inc Transaction History
Decheng Capital LLC
- $396 Billion
- Q2 2025
Shares
1 transactions
Others Institutions Holding SCYX
# of Institutions
43Shares Held
11.8MCall Options Held
0Put Options Held
0-
Federated Hermes, Inc. Pittsburgh, PA2.9MShares$2.49 Million0.0% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY2.24MShares$1.92 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.66MShares$1.42 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.23MShares$1.06 Million0.22% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC556KShares$477,7770.7% of portfolio
About SCYNEXIS INC
- Ticker SCYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 32,651,800
- Market Cap $28.1M
- Description
- SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...